These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

478 related items for PubMed ID: 23020847

  • 1. Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
    Durmus S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.
    Mol Pharm; 2012 Nov 05; 9(11):3236-45. PubMed ID: 23020847
    [Abstract] [Full Text] [Related]

  • 2. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
    Tang SC, Nguyen LN, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.
    Int J Cancer; 2014 Mar 15; 134(6):1484-94. PubMed ID: 24037730
    [Abstract] [Full Text] [Related]

  • 3. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.
    Tang SC, Lagas JS, Lankheet NA, Poller B, Hillebrand MJ, Rosing H, Beijnen JH, Schinkel AH.
    Int J Cancer; 2012 Jan 01; 130(1):223-33. PubMed ID: 21351087
    [Abstract] [Full Text] [Related]

  • 4. P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain accumulation of the active sunitinib metabolite N-desethyl sunitinib.
    Tang SC, Lankheet NA, Poller B, Wagenaar E, Beijnen JH, Schinkel AH.
    J Pharmacol Exp Ther; 2012 Apr 01; 341(1):164-73. PubMed ID: 22238213
    [Abstract] [Full Text] [Related]

  • 5. Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics.
    Poller B, Iusuf D, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.
    Drug Metab Dispos; 2011 May 01; 39(5):729-35. PubMed ID: 21282407
    [Abstract] [Full Text] [Related]

  • 6. Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2).
    Kort A, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.
    Pharmacol Res; 2015 Dec 01; 102():200-7. PubMed ID: 26361725
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment.
    Lagas JS, van Waterschoot RA, van Tilburg VA, Hillebrand MJ, Lankheet N, Rosing H, Beijnen JH, Schinkel AH.
    Clin Cancer Res; 2009 Apr 01; 15(7):2344-51. PubMed ID: 19276246
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032).
    Mittapalli RK, Vaidhyanathan S, Sane R, Elmquist WF.
    J Pharmacol Exp Ther; 2012 Jul 01; 342(1):33-40. PubMed ID: 22454535
    [Abstract] [Full Text] [Related]

  • 14. P-glycoprotein (MDR1/ABCB1) controls brain accumulation and intestinal disposition of the novel TGF-β signaling pathway inhibitor galunisertib.
    Li W, Tibben M, Wang Y, Lebre MC, Rosing H, Beijnen JH, Schinkel AH.
    Int J Cancer; 2020 Mar 15; 146(6):1631-1642. PubMed ID: 31304590
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues.
    Lin F, Marchetti S, Pluim D, Iusuf D, Mazzanti R, Schellens JH, Beijnen JH, van Tellingen O.
    Clin Cancer Res; 2013 Apr 15; 19(8):2084-95. PubMed ID: 23461902
    [Abstract] [Full Text] [Related]

  • 17. Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier.
    Poller B, Wagenaar E, Tang SC, Schinkel AH.
    Mol Pharm; 2011 Apr 04; 8(2):571-82. PubMed ID: 21309545
    [Abstract] [Full Text] [Related]

  • 18. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699).
    Durmus S, Sparidans RW, van Esch A, Wagenaar E, Beijnen JH, Schinkel AH.
    Pharm Res; 2015 Jan 04; 32(1):37-46. PubMed ID: 24962512
    [Abstract] [Full Text] [Related]

  • 19. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.
    Durmus S, Xu N, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.
    Pharmacol Res; 2013 Oct 04; 76():9-16. PubMed ID: 23827160
    [Abstract] [Full Text] [Related]

  • 20. P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib.
    Li W, Sparidans RW, Wang Y, Lebre MC, Wagenaar E, Beijnen JH, Schinkel AH.
    Int J Cancer; 2018 Oct 15; 143(8):2029-2038. PubMed ID: 29744867
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.